Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Bayer symbol

Bayer bags FDA nod for early prostate cancer drug darolutamide

new competition in the market

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

FDA will maintain the pace, vows Woodcock, but warns of skills gap

Top official unconcerned by dip in approval rate

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

- PMLiVE

Ex-FDA chief Gottlieb’s quick move to pharma raises eyebrows

Will join Pfizer board

- PMLiVE

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting

25 Women Leaders in UK Healthcare

Women trailblazers helping to shape the future of healthcare (Part 1)

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links